Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Chemotherapy can cause symptoms, such as nausea and fatigue, and some patients have difficulty working during this treatment. The purpose of this study is to learn more about how chemotherapy for breast cancer affects patients' employment.
The purpose of this study is to see how well zipalertinib works to treat advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread. The cancer also has a mutation (change) in the EGFR gene. When people have an EGFR mutation, the EGFR protein on their cells can trigger cancer growth.
In this study, researchers are seeking to find the highest dose of the investigational drug BGB-16673 that can be given safely in people with lymphoma and other types of B cell cancers that have come back or continued to grow despite prior treatment. BGB-16673 degrades a protein called BTK, which helps B cells live and grow. By degrading BTK, BGB-16673 may stop or slow the growth and activity of B cells, which could lead to improvement in the symptoms associated with B cell cancers. BGB-16673 is taken orally (by mouth).
The purpose of this study is to assess the safety and effectiveness of combination therapy with zanubrutinib, obinutuzumab, and venetoclax in patients newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).
The purpose of this study is to assess the safety and effectiveness of different combinations of drugs to treat advanced clear cell renal cell carcinoma, a type of kidney cancer, in patients who have not received any prior treatment or who have recently developed worsening disease while receiving immunotherapy that targets the PD-1/PD-L1 proteins.
Anaplastic large cell lymphoma (ALCL) is a type of T-cell cancer. This cancer has a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive ALCL.
Researchers want to find the best dose of LY4066434 when given alone and with other drugs to treat solid tumors. The people in this study have cancer that has spread (advanced) or cannot be removed with surgery (inoperable). These include colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, and other solid tumors.
Researchers are assessing trametinib and azacitidine alone and with other drugs to treat leukemia in young people. The people in this study have newly diagnosed juvenile myelomonocytic leukemia (JMML).
Researchers want to see if tumor-treating fields (TTFields) are safe and practical for people with lung adenocarcinoma before surgery. Lung adenocarcinoma is a type of lung cancer. If you join this study, you will get treatment with TTFields for up to 3 weeks before lung cancer surgery.
This study is assessing the safety and effectiveness of giving tucatinib and trastuzumab followed by standard CAPOX chemotherapy (the drugs capecitabine and oxaliplatin) in people with locally advanced rectal cancer that has not yet been treated and makes a protein called HER2. Tucatinib and trastuzumab both block HER2, which stimulates cancer cell growth.
